A case of effective use of alemtuzumab in a male patient with T-cell lymphoma


  1. Hale G., Dyer M. J., Waldmann H. et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2 (8625): 1394-1399.
  2. Dearden С. E., Matutes E., Catovsky D. Alemtuzumab in T-cell malignancies. Med. Oncol. 2002; 19 (suppl): S27-S32.
  3. Dearden С. E., Dyer M. J., Catovsky D. et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98(6): 1721-1726.
  4. Hainsworth J. D. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 2000; 5(5): 376-384.
  5. Keating M. New drugs in hematologic malignancies. Haematologica 2001; 86(N 11, suppl.): 40-42.
  6. Воробьев А. И., Виноградова Ю. Э. В кн. Воробьев А. И. (ред.) Руководство по гематологии. М.; 2003: 57-63, 113-131.
  7. Воробьев А. И., Кременецкая А. М., Лорие Ю. Ю. "Старые" и "новые" опухоли лимфатической системы. Тер. арх. 2000; 7: 9-13.
  8. Jaffe E. S., Harris N. L., Stein H., Wordiman J. W. Pathology and genetics of tumors and of haemopoietic and lymphoid tissues. WHO classifications of tumors. Lyon: IRCS Press; 2001.
  9. Birhiray R. E., Shaw C., Brettman L. et al. Phenotypic transformation of CD52 (pos) to CD52 (neg) leukemic T-cell as a mechanism for resistance to CAMPATH-1H. Leukemia 2002; 16 (5): 861-864.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies